• Inventiva reported last patient, last visit in the NATiV3 Phase 3 trial of lanifibranor in non-cirrhotic MASH.
• Topline results have not been presented; the readout is scheduled for Q4 2026.
• The trial finished the 72-week treatment period, positioning the program for a near-term efficacy and safety verdict.
• Favorable data would support a regulatory filing in H1 2027, with a potential U.S. launch targeted for 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inventiva SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609021605PRIMZONEFULLFEED1001260726) on September 02, 2026, and is solely responsible for the information contained therein.